-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $90

Benzinga·04/22/2026 14:09:18
Listen to the news
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $75 to $90.